CVS Health Corporation $CVS Shares Acquired by Kestra Advisory Services LLC

Kestra Advisory Services LLC lifted its stake in shares of CVS Health Corporation (NYSE:CVS) by 9.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 77,785 shares of the pharmacy operator’s stock after acquiring an additional 6,580 shares during the quarter. Kestra Advisory Services LLC’s holdings in CVS Health were worth $5,587,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. TOWER TRUST & INVESTMENT Co raised its position in CVS Health by 0.8% in the 4th quarter. TOWER TRUST & INVESTMENT Co now owns 15,708 shares of the pharmacy operator’s stock valued at $1,247,000 after purchasing an additional 132 shares in the last quarter. CYBER HORNET ETFs LLC increased its stake in shares of CVS Health by 4.1% during the third quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock worth $259,000 after buying an additional 134 shares during the period. LS Investment Advisors LLC raised its holdings in CVS Health by 3.9% in the fourth quarter. LS Investment Advisors LLC now owns 3,575 shares of the pharmacy operator’s stock valued at $284,000 after acquiring an additional 135 shares in the last quarter. Moss Adams Wealth Advisors LLC lifted its stake in CVS Health by 4.7% in the fourth quarter. Moss Adams Wealth Advisors LLC now owns 3,016 shares of the pharmacy operator’s stock worth $239,000 after acquiring an additional 135 shares during the last quarter. Finally, Northwestern Mutual Investment Management Company LLC grew its holdings in CVS Health by 0.3% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 40,560 shares of the pharmacy operator’s stock worth $3,219,000 after acquiring an additional 136 shares in the last quarter. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Truist Financial raised its price target on CVS to $118 and reiterated a buy rating, reinforcing bullish analyst sentiment and suggesting additional upside from current levels.
• Positive Sentiment: CVS Caremark reached a global settlement with the FTC that CVS says advances transparency and affordability in prescription drug pricing, potentially easing a major legal overhang for the pharmacy-benefit manager business. Article Title
• Positive Sentiment: Reports highlighting CVS as a 52-week high stock and a potentially attractive long-term value play are keeping momentum traders and value investors interested.
• Neutral Sentiment: CVS continued to promote Aetna provider survey results showing improved payer trust and the benefits of digital tools, which is supportive for the healthcare-services narrative but not a major immediate stock catalyst. Article Title
• Neutral Sentiment: CVS also affirmed its dividend and expanded GLP-1 support programs, which helps the investment case, though the market may still be waiting to see whether those efforts meaningfully improve employer economics and utilization trends.
• Negative Sentiment: Wall Street Zen downgraded CVS to Hold, and the stock is trading near its recent high, which could prompt some investors to question near-term valuation after a strong run.

Analyst Ratings Changes

CVS has been the topic of a number of analyst reports. Bank of America raised their price objective on shares of CVS Health from $100.00 to $110.00 and gave the company a “buy” rating in a report on Monday, June 22nd. HSBC reissued a “hold” rating and issued a $103.00 target price on shares of CVS Health in a report on Monday, July 6th. Wall Street Zen cut CVS Health from a “buy” rating to a “hold” rating in a research note on Wednesday. TD Cowen upped their price objective on CVS Health from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Finally, Truist Financial increased their price objective on CVS Health from $108.00 to $118.00 and gave the company a “buy” rating in a report on Tuesday. Twenty-one equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $105.38.

CVS Health Trading Down 0.2%

Shares of CVS stock opened at $106.01 on Thursday. The company has a market capitalization of $135.26 billion, a P/E ratio of 46.70, a price-to-earnings-growth ratio of 1.04 and a beta of 0.61. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The business’s 50 day moving average is $98.25 and its two-hundred day moving average is $84.79. CVS Health Corporation has a twelve month low of $58.50 and a twelve month high of $107.94.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. During the same period last year, the company earned $2.25 earnings per share. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities analysts forecast that CVS Health Corporation will post 7.46 EPS for the current year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd will be issued a $0.665 dividend. The ex-dividend date of this dividend is Thursday, July 23rd. This represents a $2.66 annualized dividend and a dividend yield of 2.5%. CVS Health’s payout ratio is presently 117.18%.

Insider Activity

In other news, EVP Tilak Mandadi sold 69,551 shares of the business’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president directly owned 10,133 shares in the company, valued at $907,714.14. The trade was a 87.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Larry Robbins sold 370,462 shares of the firm’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the sale, the director owned 4,824,799 shares of the company’s stock, valued at approximately $450,877,466.55. The trade was a 7.13% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 3,441,551 shares of company stock worth $323,703,977. Insiders own 0.85% of the company’s stock.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.